TNGX Quote, Financials, Valuation and Earnings

Moderna, Inc. has a net margin of 29.52% compared to Tango Therapeutics, Inc.'s net margin of -19.69%. Tango Therapeutics, Inc.'s return on equity of -56.44% beat Moderna, Inc.'s return on equity of -30.18%.

Tango Therapeutics, Inc. has a consensus price target of $13.00, signalling upside risk potential of 35.84%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that Moderna, Inc. has higher upside potential than Tango Therapeutics, Inc., analysts believe Moderna, Inc. is more attractive than Tango Therapeutics, Inc..

Tango Therapeutics, Inc. has a beta of 1.718, which suggesting that the stock is 71.771% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Tango Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tango Therapeutics, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Tango Therapeutics, Inc. quarterly revenues are $53.8M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Tango Therapeutics, Inc.'s net income of $15.9M is higher than Moderna, Inc.'s net income of -$200M. Notably, Tango Therapeutics, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tango Therapeutics, Inc. is 15.85x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of 29.52% compared to Tango Therapeutics, Inc.'s net margin of -255.85%. Tango Therapeutics, Inc.'s return on equity of -56.44% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Tango Therapeutics, Inc. has a consensus price target of $13.00, signalling upside risk potential of 35.84%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Tango Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Tango Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Tango Therapeutics, Inc. has a beta of 1.718, which suggesting that the stock is 71.771% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Tango Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Tango Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Tango Therapeutics, Inc. quarterly revenues are $53.8M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Tango Therapeutics, Inc.'s net income of $15.9M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Tango Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tango Therapeutics, Inc. is 15.85x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of 29.52% compared to Tango Therapeutics, Inc.'s net margin of --. Tango Therapeutics, Inc.'s return on equity of -56.44% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Tango Therapeutics, Inc. has a consensus price target of $13.00, signalling upside risk potential of 35.84%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 163.74%. Given that Viking Therapeutics, Inc. has higher upside potential than Tango Therapeutics, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Tango Therapeutics, Inc..

Tango Therapeutics, Inc. has a beta of 1.718, which suggesting that the stock is 71.771% more volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Tango Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tango Therapeutics, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Tango Therapeutics, Inc. quarterly revenues are $53.8M, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Tango Therapeutics, Inc.'s net income of $15.9M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Tango Therapeutics, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tango Therapeutics, Inc. is 15.85x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of 29.52% compared to Tango Therapeutics, Inc.'s net margin of 52.48%. Tango Therapeutics, Inc.'s return on equity of -56.44% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Tango Therapeutics, Inc. has a consensus price target of $13.00, signalling upside risk potential of 35.84%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $70.67 which suggests that it could grow by 127.96%. Given that XOMA Royalty Corp. has higher upside potential than Tango Therapeutics, Inc., analysts believe XOMA Royalty Corp. is more attractive than Tango Therapeutics, Inc..

Tango Therapeutics, Inc. has a beta of 1.718, which suggesting that the stock is 71.771% more volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.919%.

Tango Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Tango Therapeutics, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Tango Therapeutics, Inc. quarterly revenues are $53.8M, which are larger than XOMA Royalty Corp. quarterly revenues of $9.4M. Tango Therapeutics, Inc.'s net income of $15.9M is higher than XOMA Royalty Corp.'s net income of $10.3M. Notably, Tango Therapeutics, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 41.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tango Therapeutics, Inc. is 15.85x versus 10.78x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.